Veracyte Inc (VCYT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Veracyte Inc (VCYT) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($44.76 Million) by net assets ($1.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Veracyte Inc fund operations to measure how many days the company can operate on defensive assets alone.
Veracyte Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Veracyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Veracyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veracyte Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Keboda Technology Co Ltd
SHG:603786
|
0.045x |
|
TIME Dotcom Bhd
KLSE:5031
|
0.104x |
|
Digital China Group Co Ltd
SHE:000034
|
-0.106x |
|
NH Hoteles
MC:NHH
|
0.219x |
|
PNB Housing Finance Limited
NSE:PNBHOUSING
|
-0.215x |
|
Acadia Realty Trust
NYSE:AKR
|
0.012x |
|
Assured Guaranty Ltd
F:DHU
|
0.007x |
|
Black Stone Minerals LP
NYSE:BSM
|
0.058x |
Annual Cash Flow Conversion Efficiency for Veracyte Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Veracyte Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Veracyte Inc (VCYT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.18 Billion | $75.10 Million | 0.064x | +50.77% |
| 2023-12-31 | $1.04 Billion | $44.22 Million | 0.042x | +504.37% |
| 2022-12-31 | $1.08 Billion | $7.54 Million | 0.007x | +124.30% |
| 2021-12-31 | $1.10 Billion | $-31.62 Million | -0.029x | -25.09% |
| 2020-12-31 | $421.23 Million | $-9.71 Million | -0.023x | -70.80% |
| 2019-12-31 | $239.46 Million | $-3.23 Million | -0.013x | +92.04% |
| 2018-12-31 | $79.75 Million | $-13.52 Million | -0.170x | +73.61% |
| 2017-12-31 | $37.23 Million | $-23.91 Million | -0.642x | -36.79% |
| 2016-12-31 | $59.58 Million | $-27.98 Million | -0.470x | +10.73% |
| 2015-12-31 | $51.25 Million | $-26.96 Million | -0.526x | +21.22% |
| 2014-12-31 | $41.37 Million | $-27.63 Million | -0.668x | -96.75% |
| 2013-12-31 | $56.44 Million | $-19.16 Million | -0.339x | +76.79% |
| 2012-12-31 | $4.90 Million | $-7.17 Million | -1.462x | +7.76% |
| 2011-12-31 | $8.53 Million | $-13.52 Million | -1.585x | -- |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more